



HHS Public Access

Author manuscript

Food Chem Toxicol. Author manuscript; available in PMC 2018 July 01.

Published in final edited form as:

Food Chem Toxicol. 2017 July ; 105: 387–397. doi:10.1016/j.fct.2017.05.004.

Arsenic metabolism and one-carbon metabolism at low-moderate arsenic exposure: evidence from the Strong Heart Study

Miranda Jones Spratlen¹, Mary V. Gamble², Maria Grau-Perez², Chin-Chi Kuo^{3,4}, Lyle G. Best⁵, Joseph Yracheta⁵, Kevin Francesconi⁶, Walter Goessler⁶, Yasmin Mossavar-Rahmani⁷, Meghan Hall⁸, Jason G. Umans^{9,10}, Amanda Fretts¹¹, and Ana Navas-Acien^{1,2}

¹Department of Environmental Health, Johns Hopkins Bloomberg School of Public Health Department, 615 N. Wolfe Street, Baltimore, MD, 21205

²Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, 722 W 168th St, New York, NY 10032

³Kidney Institute and Division of Nephrology, Department of Internal Medicine, China Medical University Hospital and College of Medicine, China Medical University, No.91, Hsueh-Shih Road, Taichung, Taiwan 40402

⁴Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD, 21205

⁵Missouri Breaks Industries Research, Inc., HC 64 Box 52, Timber Lake, SD 57656

⁶Institute of Chemistry - Analytical Chemistry, Universitätsplatz 1/1, 8010 Graz, Austria

⁷Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461

⁸Department of Epidemiology, Columbia University Mailman School of Public Health, 722 W 168th St, New York, NY 10032

⁹MedStar Health Research Institute, 6525 Belcrest Rd #700, Hyattsville, MD 20782

¹⁰Georgetown-Howard Universities Center for Clinical and Translational Science, 4000 Reservoir Road Washington, DC 20007

¹¹Department of Epidemiology, University of Washington, 1959 NE Pacific Street, Health Sciences Bldg, F-262 Box 357236, Seattle, WA 98195

Corresponding author: Miranda J. Spratlen (mjones47@jhu.edu), Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Room W7015, Baltimore, MD 21218, Tel: 914-441-9826.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. INTRODUCTION

Inorganic arsenic (iAs) in food and water is a major global health concern. An established carcinogen, chronic arsenic exposure also increases the risk of cardiovascular disease, respiratory disease, neurologic deficits, and diabetes.(Chen et al. 2011; Council 2001; Kuo et al. 2013; Moon et al. 2012; Naujokas et al. 2013; Tyler and Allan 2014; Wu et al. 2014) After ingestion, iAs (arsenate and arsenite) is metabolized into mono- and di-methylated arsenicals (MMA and DMA); DMA has a shorter circulating half-life and is more rapidly excreted through the urine as compared to iAs.(Aposhian and Aposhian 2006; Challenger 1951; Cullen WR 1989; Hayakawa et al. 2005; Naranmandura et al. 2006; Vahter 2002) The urinary distribution of arsenic metabolites across human populations ranges from 10–30% for iAs, 10–20% for MMA and 60–80% for DMA.(Chiou et al. 1997; Del Razo et al. 1997; Hopenhayn-Rich et al. 1996; Navas-Acien et al. 2009; Vahter 2000) Higher percentages of iAs (iAs%) and MMA (MMA%) and lower percentages of DMA (DMA%) in urine are thought to reflect a less efficient arsenic metabolism profile and have been associated with higher risk of cancer, skin lesions and cardiovascular disease.(Chen et al. 2003a; Chen et al. 2003b; Chen et al. 2005; Del Razo et al. 1997; Hsueh et al. 1997; Steinmaus et al. 2006; Wu et al. 2006; Yu et al. 2000) Conversely, higher DMA% and lower MMA% have been associated with diabetes, metabolic syndrome and higher body mass index.(Chen et al. 2012; Del Razo et al. 2011; Kuo et al. 2015; Mendez et al. 2016; Nizam et al. 2013; Wang et al. 2007) Understanding non-modifiable (genetics, sex, life-stage) and modifiable (smoking, alcohol intake, kidney function, body mass index, nutrition) determinants of arsenic metabolism is important given the role of arsenic metabolism in arsenic toxicity. (Balakrishnan et al. 2016; Council 2013; Gribble et al. 2013; Jansen et al. 2016)

Nutritional status is a major susceptibility factor for arsenic-related disease, at least in part through the impact of nutrition on one-carbon metabolism (OCM).(Council 2013) OCM, a network of interrelated biochemical reactions dependent on sufficient intake of vitamin B₂ (riboflavin), vitamin B₆, folate (vitamin B₉) and vitamin B₁₂, plays an essential role in methylation processes throughout the body, including the methylation reactions involved in arsenic metabolism (Figure 1).(Hall and Gamble 2012; Howe et al. 2014) In studies from Bangladesh, both cross-sectional (Gamble et al. 2005) and folic acid supplementation trials demonstrated (Gamble et al. 2006; Peters et al. 2015) that higher folate is associated with increased arsenic methylation efficiency, resulting in higher DMA% and lower iAs% and MMA% in urine and in reduced blood arsenic concentrations. In cross-sectional studies, greater dietary intake of vitamins B₁₂ and B₂ (Heck et al. 2007) and higher plasma B₁₂ (Hall et al. 2009a) have been associated with lower iAs% and higher MMA%, in Bangladeshi adults. Further, both epidemiologic (Chung et al. 2006; Pilsner et al. 2009; Zablotska et al. 2008) and experimental studies (Acharyya et al. 2015; Bhattacharjee S 2013) have reported OCM nutrients to be associated with lower risk for arsenic-related disease.

The generalizability of the OCM findings in Bangladesh to US populations with low-moderate arsenic exposure and different dietary patterns is unclear. We evaluated the association of OCM nutrients with arsenic metabolism biomarkers in the Strong Heart Study (SHS), a population-based cohort study initiated to assess cardiovascular risk factors in American Indian adults residing in Arizona, Oklahoma and North and South Dakota. We

used dietary intake estimates of B₂, B₆, folate and B₁₂ as measures of OCM nutrients and percentages of urinary inorganic arsenic (iAs%) and its methylated metabolites (MMA% and DMA%), as measures of arsenic metabolism. We also modeled the complexity of both arsenic metabolism profiles and nutrition intake through the use of principal component analysis (PCA).

2. METHODS

2.1 Study Population

The SHS recruited 4,549 American Indians from 13 tribes located in Arizona, Oklahoma and North and South Dakota. Eligible participants were men and women aged 45–74 years at the baseline visit in 1989–1991. The overall participation rate was 62%. All participants provided informed consent and study protocols were approved by multiple institutional review boards, community members and The Indian Health Service. In 2016, one of the communities withdrew their consent for participating in future studies, reducing the overall sample size to 3,516. The final version of this manuscript, along with a lay summary, was sent to, and approved by, all remaining communities.

At the baseline visit (1989–1991), a random sample of 50 males and 50 females from each age decade and at each study site (n=722; 508 after excluding the community that withdrew consent) was selected to participate in a self-administered food frequency questionnaire (FFQ), which provided estimated long-term daily average intake of folate and vitamins B₂, B₆ and B₁₂ in milligrams.(Committee 1989) We excluded 94 participants with missing data on urine arsenic, and 9 participants missing data on education, alcohol intake, smoking status, body mass index (BMI), estimated glomerular filtration rate (eGFR), and urine creatinine, leaving 405 participants for this study. Participants included in this study were similar to the overall study population on most variables of interest, with the exception of being slightly older than the full cohort (Supplemental Material Table S1).

2.2 Data Collection

Baseline visits included bio-specimen collection, a physical exam, and an interview-administered questionnaire. Visits were performed by trained and certified examiners according to a standardized protocol. Details have been described previously.(Lee et al. 1990)

2.2.1 Urine Arsenic Metabolites—Morning spot urine samples were collected during baseline visit in polypropylene tubes, frozen within 1 to 2 hours of collection, shipped buried in dry ice and stored at <-70°C in the Penn Medical Laboratory, MedStar Research Institute, Washington, DC.(Lee et al. 1990) The freezers have been operating under a strict quality control system to guarantee secure sample storage. For arsenic analyses, urine samples were thawed in 2009–2010, and up to 1.0 mL from each urine sample was transferred to a small vial, transported on dry ice to the Trace Element Laboratory at Graz University, Austria and stored at <-70°C until analyses.(Scheer et al. 2012)

Quality control and quality assurance methods for urine arsenic analysis have been described in detail.(Scheer et al. 2012) Urine concentrations of arsenite, arsenate, methylarsonate

(MMA) and dimethylarsinate (DMA) were measured using high performance liquid chromatography/inductively coupled plasma-mass spectrometry (HPLC/ICPMS). The limits of detection were 0.1 µg/L for arsenite, arsenate, MMA and DMA. The inter-assay coefficients of variation for arsenite and arsenate, MMA and DMA were 5.6%, 6.3%, 3.5% and 4.4% respectively. Urine arsenobetaine concentrations were measured using cation-exchange HPLC/ICPMS together with other less common arsenic cations, and the low concentration measured (median (IQR): 0.73 (0.49, 1.47) µg/L) confirmed seafood consumption in this population was infrequent. The limit of detection for urine arsenobetaine was 0.1 µg/L and the inter-assay coefficient of variation was 6.9%. No participants in this analysis had arsenic species below the limit of detection.

2.2.2 Nutrition Variables—Dietary intake of OCM-related micronutrients was measured during the baseline visit through estimated daily averages of dietary intake of vitamins B₂, B₆, folate and B₁₂ in the past-year. These variables, as well as total caloric intake, were measured through an interviewer-administered Block 119-item food frequency questionnaire (FFQ). The Block questionnaire is one of the most widely used questionnaires with demonstrated reliability and validity.(Fretts et al. 2012) Each participant was asked how often, on average, a particular food was consumed during the past year using measures of consumption frequency and portion size adjustment.(Fretts et al. 2012)To enhance accuracy of the questionnaire in this cohort, additional questions relating to foods commonly consumed by American Indians were added.(Fretts et al. 2012) Of note, folate was calculated based on dietary intake alone as doses of folic acid supplementation were not available (only whether supplements were taken or not) and mandatory folic acid fortification was not implemented by the date of FFQ administration.

2.2.3 Other Variables—Sociodemographic (age, sex, and education) and life-style (vitamin supplementation use and drinking and smoking status) study variables were ascertained through a standardized questionnaire (separate from the FFQ) by trained and certified interviewers.(Lee et al. 1990) Height and weight measurements for BMI calculation (weight in kilograms divided by height in meters squared) were conducted during the physical exam. Urine creatinine was measured from the spot urine samples collected for arsenic analysis using an automated alkaline picrate methodology.(Lee et al. 1990) eGFR was calculated from creatinine, age and sex using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, as previously described.(Shara et al. 2012)

2.3 Statistical Analysis Methods

To evaluate arsenic metabolism, we computed the relative proportions of inorganic and methylated arsenic metabolites by dividing each metabolite concentration over the sum of those species x 100. In this way, a methylation profile was estimated for each participant, consisting of iAs%, MMA% and DMA%, totaling to 100%. We also evaluated arsenic metabolism using principal component analysis (PCA), as recently proposed.(Balakrishnan et al. 2016; Jansen et al. 2016) PCA was conducted using each arsenic species percentage, then scaling them. PCA is useful in the analysis of arsenic metabolism biomarkers because it removes the inter-dependence of the three biomarkers (iAs%, MMA% and DMA%) allowing for an improved, and potentially more biologically meaningful, interpretation of

each metabolite. Previous studies have suggested that the first arsenic metabolism principal component (As metabolism PC1) reflects the ability to produce DMA (i.e., the secondary methylation step) while the second arsenic metabolism principal component (As metabolism PC2) reflects the conversion of iAs to MMA (i.e., the primary methylation step). (Balakrishnan et al. 2016; Jansen et al. 2016) Inorganic arsenic exposure was estimated as the sum of urinary concentrations of iAs, MMA and DMA (Σ As). Σ As concentrations were right skewed and log-transformed for the analyses.

The analysis of dietary estimates of OCM nutrients (vitamin B₂, vitamin B₆, folate and vitamin B₁₂) requires adjustment for total caloric intake in most analyses. Because nutrient and total caloric intake variables were measured from the same questionnaire, their errors are strongly correlated. To cancel out these errors and improve the validity of energy-adjusted nutrients, nutrient density and residual methods have been suggested over simply including caloric intake as a variable in regression models. (Rhee et al. 2014) We used a residual analysis approach and regressed each log-transformed vitamin intake on log-transformed total caloric intake. We then added the mean log-transformed value of each nutrient to the nutrient residuals to create calorie-corrected nutrient variables. Because some OCM nutrients share common dietary sources and they are metabolically inter-dependent, we also used PCA to identify major PCs across log-transformed, calorie-corrected OCM nutrients.

Arsenic methylation patterns were compared across sociodemographic, health, nutrition and behavioral characteristic variable categories using Kruskal-Wallis tests. Pearson correlation coefficients were conducted to estimate univariate correlations between iAs%, MMA%, DMA% and calorie-corrected vitamins (vitamin B₂, vitamin B₆, folate and vitamin B₁₂) (Figure 2).

The mean difference (95% CI) of each of arsenic species percentages (iAs%, MMA%, DMA %) and arsenic metabolism principal component (As metabolism PC1 and As metabolism PC2) comparing the two highest to the lowest tertile of each calorie-corrected nutrient variable (vitamin B₂, vitamin B₆, folate and vitamin B₁₂) was estimated using linear regression models. We used the following progressive adjustments for known arsenic metabolism and nutrition intake determinants in our models evaluating arsenic metabolism both as individual arsenic species' percentages as well as principal components: model 1 adjusted for Σ As (log-transformed) and urine creatinine (log-transformed); model 2 further adjusted for age (continuous), sex, study center (Arizona, Oklahoma, North/South Dakota), BMI (continuous), smoking status (never, former, current), alcohol use (never, former, current), and eGFR (continuous); model 3 further adjusted for the other OCM calorie-corrected nutrient variables. Because adjustment for all nutrients at once can be difficult due to possible collinearity, we also used OCM PCs to evaluate the association of arsenic metabolism biomarkers with independent summary variables of calorie-corrected nutrients.

We conducted multiple sensitivity analyses. First, we evaluated the potential impact of outliers in our models using resistant regression with consistent results (data not shown). Second, we evaluated an alternative method of correcting nutrients for total caloric intake (log-transformed) using adjustment in the main regression analysis instead of the residual-

based approach, with similar findings (data not shown). Third, we used specific gravity as an alternative to urinary creatinine to account for urine dilution, with consistent results (Supplemental Material Table S2). Main analyses include adjustment for urinary creatinine as it has been shown to affect arsenic metabolism, possibly through the competition for methyl groups in the synthesis of creatine, the precursor to creatinine. (Peters et al. 2015) Urinary creatinine reflects both dietary creatine intake (primarily from meat) and endogenous synthesis of creatine. In addition, we ran regressions with and without a participant with an outlying high (>100 μ g) value for B₁₂, again with consistent results (data not shown). We also ran regressions with and without participants reported to take folic acid or multivitamin supplements (n=9) with consistent results (data not shown). Further, to address potential concerns regarding DMA from food sources at low levels of arsenic exposure, we stratified by center due to geographical differences in exposure sources (water is a major source in Arizona and North and South Dakota, while in Oklahoma the predominant source is food). Results were similar in both areas of lower exposure (Oklahoma) and higher exposure (Arizona and Dakotas) (Supplemental Material Table S2). Finally, exploratory analyses were conducted to investigate potential pairwise interactions between each OCM nutrient. A joint categorical variable reflecting high (equal to or greater than the median) and low (below the median) intake, as well as quantitative interaction terms, of each OCM nutrient pair, was created to assess these relationships (Supplemental Material Table S3).

2.3.1 Sample Size Justification—Our sample size was fixed as our analysis was based on previously collected data. Therefore, we conducted a minimally detectable effect estimate for each of our main outcomes (iAs%, MMA% and DMA%). We used a sample size of 405 and 80% power for each calculation. For iAs%, using a mean of 8.4 and standard deviation of 4.7, we computed the minimally detectable difference to be 0.66. For MMA%, using a mean of 14.7 and standard deviation of 5.3, we computed the minimally detectable difference to be 0.70. For DMA%, using a mean of 76.9 and standard deviation of 8.8, we computed the minimally detectable difference to be 1.23.

3. RESULTS

3.1 Participant Characteristics

Median (IQR) percentages for arsenic metabolism biomarkers were 7.1 (5.2–10.7)% for iAs %, 13.7 (11.3–17.7)% for MMA%, and 78.2 (71.6–83.3)% for DMA% (Table 1). Median (IQR) for arsenic species concentrations were 0.74 (0.33, 1.58) μ g/L for iAs, 1.36 (0.71, 2.65) μ g/L for MMA and 7.59 (4.69, 13.52) μ g/L for DMA. Median (IQR) daily intake for OCM nutrients were 1.4 (0.9–2.0) mg for vitamin B₂, 1.2 (0.8–1.9) mg for vitamin B₆, 207 (120.4–336.7) μ g for folate, and 3.0 (1.7–5.7) μ g for vitamin B₁₂. Several characteristics were associated with higher iAs%, higher MMA% and lower DMA%, including being male, lower BMI, current smoker and current alcohol drinker. Characteristics associated with just higher iAs% included being younger, having eGFR > 60 mL/min/1.73 m² and having lower intake of B₆ and folate. Compared to tertiles 1 and 3, participants in the 2nd tertile of urine creatinine had lower iAs% and higher DMA% (Table 1). Pearson correlation coefficients were moderately positive for iAs% and MMA% (0.54), and strongly negative between both

iAs% and MMA% with DMA% (-0.86 and -0.89, respectively) (Figure 2). All OCM nutrition variables were positively correlated with each other both before and after correcting for caloric intake. Calorie-corrected nutrient correlations ranged from 0.23 between vitamin B₁₂ and vitamin B₆ to 0.70 between vitamin B₂ and folate. Correlations between OCM nutrients were negative with both MMA% and iAs% (ranging from -0.01 for iAs% and vitamin B₁₂ to -0.13 for iAs% and vitamin B₆); and positive with DMA% (ranging from 0.03 with vitamin B₁₂ to 0.13 with vitamin B₆)(Figure 2).

Variance in arsenic methylation patterns were summarized in two principal components. Arsenic metabolism principal component 1 (As PC1) explained 84.6% of the variance in arsenic species biomarkers and reflected higher DMA% and lower iAs% and MMA% (Table 2). Arsenic metabolism principal component (As PC2) explained 15.4% of the variance and reflected higher MMA% and lower iAs%, independent of DMA%. Variance in OCM nutrients was summarized in four principal components (Table 2). OCM PC1 explained 60.1% of the variance in OCM nutrients and reflected higher intake of all four B-vitamins. OCM PC2 explained 22.7% of the variance and reflected higher vitamin B₁₂ intake and lower intake of vitamin B₆ and folate. OCM PC3 explained 10.3% of the variance and reflected higher folate and B₂ intake and lower intake of vitamins B₆ and vitamin B₁₂. OCM PC4 explained 6.9% of variance and reflected higher intake of vitamin B₁₂ and folate and lower intake of the other nutrients.

3.2 Association of One-Carbon Metabolism Nutrients and Arsenic Metabolism Biomarkers

OCM nutrients, specifically vitamins B₆ and B₂, were associated with more efficient arsenic methylation profiles. In fully adjusted models (Table 3, Model 2), higher intake of vitamins B₂ and B₆ were associated with lower iAs%, lower MMA% and higher DMA%. Compared to tertile 1, participants in tertile 3 of vitamin B₂ intake had 1.00 (95% CI: -2.00, 0.00)% lower iAs%, 1.36 (95% CI: -2.48, -0.23)% lower MMA% and 2.36 (95% CI: 0.54, 4.18)% higher DMA%. Correspondingly, participants in tertile 3 of vitamin B₆ intake had 1.36 (95% CI: -2.35, -0.37)% lower iAs%, 1.57 (95% CI: -2.69, -0.45)% lower MMA% and 2.93 (95% CI: 1.13, 4.74)% higher DMA%. These associations, with the exception of vitamin B₂ and iAs%, remained statistically significant and similar in magnitude after further adjustment for all OCM nutrients (Table 3, Model 3).

In fully adjusted models without adjustment for other OCM nutrients (Table 3, Model 2), folate showed a similar association with arsenic metabolism biomarkers as vitamins B₂ and B₆, although they were weaker, not statistically significant, and stronger for the second tertile than the third. For example, participants in tertile 2 of folate intake compared to tertile 1 had 0.93 (95% CI: -2.06, 0.20) lower MMA% but participants in tertile 3 of folate intake compared to tertile 1 had only 0.18 (95% CI: -1.30, 0.93) lower MMA%. With further adjustment for other OCM nutrients, the association with tertile 2 of folate was attenuated, whereas tertile 3 reversed direction for all arsenic metabolism biomarkers, although the associations remained not-statistically significant. Again, using MMA% as an example, compared to tertile 1, tertile 2 was associated with 0.29 (95% CI: -1.46, 0.88) lower MMA% and tertile 3 was as associated with 1.27 (95% CI: -0.08, 2.62) greater MMA%. The

corresponding associations with vitamin B₁₂ were weaker and not statistically significant in any model.

When modeling arsenic metabolism using PCA, tertile 3 of vitamins B₂ and B₆ intake were associated with higher As metabolism PC1, reflecting higher DMA% and lower iAs% and MMA% (Table 4). No significant associations were observed with any of the OCM nutrients and As metabolism PC2. In models using OCM PCs instead of the original nutrient variables, OCM PC1, reflecting higher intake of all OCM nutrients, was negatively associated with iAs% and MMA% and positively associated with DMA% and As metabolism PC1 (Table 4). OCM PC2, representing mostly high vitamin B₁₂, possibly reflecting meat intake, was not associated with arsenic methylation profiles. OCM PC3, reflecting higher intake of vitamin B₂ and folate with lower vitamin B₆, was positively associated with higher iAs% and MMA% and negatively associated with DMA% and As metabolism PC1, although none of the associations were statistically significant. OCM PC4, reflecting high folate and vitamin B₁₂ and low vitamin B₆ and B₂, was positively associated with iAs% and MMA%, and negatively with DMA% and As metabolism PC1, however, only the association with MMA% was statistically significant. In analyses evaluating the joint effect of OCM nutrients in pairs, we found an independent additive association between intake of vitamins B₆ and B₂ with arsenic metabolism biomarkers. Mean DMA% was 2.76 (95% C:I 0.88, 4.65)% higher for participants with both vitamins B₆ and B₂ above (high) versus below (low) the median, 2.02 (95% CI: -0.10, 4.14)% higher for participants with only high B₆ and 1.08 (95%CI -1.09, 3.24)% higher for participants with only high B₂ (Supplemental Material Table S3). The joint association was not different from additive (p-value for interaction 0.83). For vitamin B₆ and folate, compared to participants with low intake of both vitamins, high folate intake with low B₆ was associated with 1.39 (95% CI: 0.19, 2.58)% higher iAs% and 2.58 (95% CI: -4.77, -0.93)% lower DMA% while high folate intake with high vitamin B₆ was associated with 1.03 (95% CI: -2.01, -0.05) lower iAs% and 1.65 (95% CI: -0.14, 3.44)% higher DMA%. The p-value for interaction, supporting an antagonistic interaction, between folate and B₆ was 0.01 for iAs% and 0.001 for DMA% (no interaction was found for MMA%).

4. DISCUSSION

Dietary intake of OCM nutrients was associated with urinary arsenic methylation patterns in a population of rural American Indian adult men and women exposed to low-moderate levels of inorganic arsenic from drinking water and food. In general, higher intake of B-vitamins, in particular B₂ and B₆, was associated with lower percentages of iAs and MMA and higher percentages of DMA, a profile suggested to reflect enhanced arsenic metabolism. These associations persisted for vitamins B₂ and B₆ after adjustment for sociodemographic factors, smoking, alcohol intake, BMI, and kidney function, as well as all OCM nutrients. The joint association for vitamins B₂ and B₆ was independent and not different from additive. For vitamin B₁₂, a vitamin with a relatively high intake in the study population, there was no association with arsenic metabolism biomarkers, a finding that is consistent with results from other populations with generally adequate vitamin B₁₂ intake.(Gamble et al. 2005; Hall et al. 2009b) The association between folate intake and arsenic metabolism in the main analyses was not clear. In joint analyses, an antagonistic association was found between

folate and vitamin B₆, with higher folate being associated with higher DMA% and lower iAs% only in the presence of high vitamin B₆. However, these results should be interpreted with caution given the high correlation between B₆ and folate.

OCM is critical in the biosynthesis of purines and thymidylate as well as the generation of methyl groups.(Ralph Carmel 2001) OCM facilitates the generation of S-adenosylmethionine (SAM) which serves as a methyl donor for numerous substrates. These substrates are essential to multiple biological processes including cellular signaling, DNA methylation, the synthesis of proteins, lipids, hormones and carbohydrates, and arsenic metabolism.(Ralph Carmel 2001) A product of SAM-dependent methylation reactions, s-adenosylhomocysteine, is hydrolyzed to homocysteine (Hcys), which can be remethylated to form methionine and activated to regenerate SAM.(Ralph Carmel 2001) OCM functioning, and adequate methyl group availability, is dependent on essential nutrients including folate, vitamin B₁₂, vitamin B₆, and vitamin B₂ (Figure 1).

Numerous studies conducted in Bangladesh have characterized the relationship between OCM nutrients and arsenic metabolism in populations exposed to high levels of arsenic. Randomized controlled trials (RCTs) (Gamble et al. 2006; Peters et al. 2015) have focused on folic acid given its key role in the recruitment of methyl groups, which are required for methylation reactions in the OCM pathway.(Peters et al. 2015) Results from cross-sectional studies (Gamble et al. 2005; Hall et al. 2007; Li et al. 2008) have also shown associations between higher plasma folate and enhanced arsenic metabolism, consistent with increases in urinary DMA% and decreases in iAs% and MMA% seen in RCTs. Collectively, these studies provide strong evidence for the temporality of these associations. Cross-sectional dietary intake studies of folate and arsenic metabolism from Bangladesh(Heck et al. 2007), Mexico(Lopez-Carrillo et al. 2016) and the U.S.(Steinmaus et al. 2005), however, have been inconsistent.

Evaluation of OCM nutrients beyond folate, including vitamins B₂, B₆ and B₁₂, all of which play important roles in OCM (Figure 1), has not been as extensive, lacking evidence from RCTs. Higher vitamin B₁₂ (plasma(Hall et al. 2009a) and dietary intake (Heck et al. 2007; Lopez-Carrillo et al. 2016)) was associated with lower iAs% and higher MMA% in some studies but not in studies with a lower prevalence of B₁₂-deficiency.(Gamble et al. 2005; Gamble et al. 2006; Hall et al. 2009b) These results have led to the hypothesis that increases in vitamin B₁₂ may promote the first step of arsenic methylation, leading to higher MMA% and lower iAs%.(Hall et al. 2009a; Howe et al. 2014) The study reporting plasma B₁₂ levels being associated with lower iAs% and higher MMA%, by design, over-selected participants having moderate- to severe-B₁₂ deficiency. The predomination of the methylation of iAs to MMA over MMA to DMA may be specific to under-nourished populations exposed to high levels of arsenic, due to a competition for available methyl groups.(Howe et al. 2014) In our population, characterized by adequate or even high vitamin B₁₂ intake, we found no association with arsenic metabolism. This may be because vitamin B₁₂ truly does not affect arsenic metabolism in populations where vitamin B₁₂ intake is high. However, it is also possible our lack of significant associations for vitamin B₁₂ was due to our study being underpowered to detect an effect size of that magnitude.

Three dietary intake studies, one conducted in the U.S.(Steinmaus et al. 2005), one conducted in women from Mexico (Lopez-Carrillo et al. 2016) and one conducted in Bangladesh,(Heck et al. 2007) reported null results for vitamin B₆. The Bangladeshi dietary intake study, however, found similar associations between vitamin B₂ and arsenic metabolism as had been reported for vitamin B₁₂; higher vitamin B₂ intake was associated with lower iAs% but higher MMA%.(Heck et al. 2007) Associations for vitamin B₂ were null in the other two dietary intake studies.(Steinmaus et al. 2005)

Our analysis on the association between OCM nutrients and arsenic metabolism fills in gaps in our understanding of this relationship in a cohort relevant to the general U.S. population. The SHS population is better nourished (38% of participants from the Bangladeshi dietary intake study were underweight compared to just one participant in our study) and exposed to lower levels of arsenic than the populations studied in Bangladesh. Further, dietary patterns differ substantially between the two populations: the SHS diet generally includes fewer fresh fruits and vegetables (significant sources of vitamin B₆ and folate) (Figure 3) and more meat/protein (significant sources of B₂ and B₁₂ and intake and has been associated with arsenic metabolism (Heck et al. 2007; Steinmaus et al. 2005)) than typical Bangladeshi diets.(Berg et al. 2012; Fretts et al. 2012) This is reflected in our participants' higher levels of vitamins B₁₂ and B₂ and lower levels of folate and vitamin B₆ than in Bangladesh (Supplemental Material Table S4). Participants in the dietary intake study conducted among Mexican women had OCM nutrient intake patterns more similar to those in the Bangladeshi dietary intake study.(Heck et al. 2007; Lopez-Carrillo et al. 2016)

To our knowledge, only one other study has evaluated OCM nutrients and arsenic metabolism in a U.S. population.(Steinmaus et al. 2005) This study, conducted in individuals from Western Nevada and Kings County, California, exposed to arsenic levels in drinking water generally above 10 µg/L(Steinmaus et al. 2003), found no association between dietary intake of OCM nutrients and arsenic metabolism; however, the study was small (N=87), some OCM nutrients were not available (no evaluation of vitamin B₁₂), and the majority of the population was male (75%) with a large percentage having a history of bladder cancer (26%).(Steinmaus et al. 2005)

In our study, the strongest associations between vitamin intake and arsenic metabolism were for the least extensively studied OCM nutrients, vitamins B₂ and B₆. Greater intake of vitamins B₂ and B₆ were associated with higher DMA% and lower iAs% and MMA%. Our PCA results support these findings with greater intake of vitamins B₂ and B₆ also being associated with higher As metabolism PC1, which reflects lower iAs% and MMA% and higher DMA%. Because metabolism of arsenic first involves the conversion of iAs to MMA and then the conversion of MMA to DMA, As metabolism PC1 may represent overall methylation to DMA, or the secondary arsenic methylation index.

The magnitude of increases in DMA% and decreases in MMA% for participants in the third versus first tertile of intake for B₂ and B₆ were significant but modest (ranging from 1.5 to 3 percentage point differences). Translating this into clinical relevance, increasing intake of vitamin B₆ by 1.06 mg, for example, reflecting the increase in intake needed to move those at the median of the first tertile to the median of the third tertile of vitamin B₆ intake, could

result in MMA% 1–2 percentages lower. Although on the individual level, this may appear small, on the population level it could translate to significant effects on health outcomes. For example, a case-control study from Chile reported a 1.11 (1.06, 1.17) and 1.05 (1.00, 1.10) greater odds of skin cancer and bladder cancer, respectively, for each 1% increase in MMA%.(Melak et al. 2014) Further, in a Bangladesh-based trial, folate deficient participants received folic acid supplementation for 12 weeks. This resulted in a decline in MMA% in urine from 13% to 10% yet a 22% reduction in blood MMA levels and 14% reductions in participants' total blood arsenic.(Gamble et al. 2006; Gamble et al. 2007)

Further, results from our pairwise interactions suggest there is an additive independent association for high intake of vitamins B₂ and B₆ with enhanced arsenic metabolism. Our findings add evidence that vitamins B₂ and B₆, less studied B-vitamins involved in OCM, may also affect arsenic metabolism in the same direction as has been reported for folate; and perhaps, play a stronger role in arsenic metabolism than folate in well-nourished protein-sufficient populations. This finding is also supported by the OCM PC analysis. OCM PC1, reflecting higher intake of all four vitamins, was associated with lower iAs% and MMA% and higher DMA% and As metabolism PC1. However, OCM PC4, reflecting low B₂ and B₆ intake and high folate and B₁₂ intake, was significantly associated with higher MMA% and non-significantly associated with higher iAs% and lower DMA%. Thus, despite high folate and B₁₂ intake, low intake of B₂ and B₆ (e.g., a diet with low intake of dairy, poultry and fruit but high intake of green vegetables and certain fish) resulted in lower arsenic metabolism efficiency. This result for PC4 is consistent with the joint analysis for folate and vitamin B₆, where high folate was associated with lower arsenic metabolism efficiency in the presence of low vitamin B₆ but with higher arsenic metabolism efficiency with high B₆ intake. These findings suggest that high folate alone may not enhance arsenic metabolism in this population. Although we cannot disregard that these findings could be related to measurement error of folate nutritional status in the absence of plasma folate data, additional research is needed to evaluate if this pattern is consistent in other populations. Overall, these results suggest that, as it has been reported for plasma folate in undernourished and low-protein populations, increasing levels of OCM nutrients, specifically B₂ and B₆, can enhance arsenic methylation capacity in a well-nourished protein-sufficient population exposed to low-moderate arsenic.

In independent linear regressions analyses for folate, the stronger association with MMA% and DMA% for participants in the second tertile of folate rather than the third tertile, and the reversing of direction in tertile 3 after adjustment for other nutrients, is difficult to interpret. It could be related to measurement error from the difficulty of dietary folate measurement. We did not calculate dietary folate equivalents (DFEs), which are used to incorporate all sources of folate intake, in addition to accounting for the higher bioavailability of folic acid from supplements and fortified foods compared with naturally occurring folate in foods. (Bailey 1998; Park et al. 2013) However, sensitivity analyses excluding participants reporting vitamin supplementation use yielded consistent results, and mandatory fortification of foods with folic acid was not implemented in the United States until 1998 (almost ten years after data collection). It is also possible the patterns seen for folate and arsenic metabolism in our analysis are not consistent with other studies due to interactions with intake of other vitamins, unmeasured confounding and/or oxidation of food folates during

cooking. Studies in well-nourished populations exposed to a broad range of folate through food fortification and supplementation use, with measurements of both folate intake and biomarkers, are necessary to assess the dose-response relationship of folate intake with arsenic metabolism.

Limitations of our study include relying on self-reported dietary data from the FFQ, a dietary assessment tool that is associated with underestimates of intake, particularly energy and protein.(Mossavar-Rahmani et al. 2015; Prentice et al. 2011) Further, self-reporting intake over a full year may introduce measurement error due to recall bias. Confirmation of findings through evaluation of nutrition biomarkers would have enhanced analyses and study interpretation. Still, correlations between dietary intake estimates and plasma biomarkers of vitamin B₁₂ and folate reported in a recent feeding study ($r=0.63$ for Vitamin B₁₂ and $r=0.66$ for DFE) support the strength of intake estimates to reflect internal vitamin levels.(Lampe et al. 2017) In addition, data were lacking on other nutrients involved in OCM, such as methionine and choline, which would have allowed a more comprehensive understanding of the full impact of OCM and arsenic metabolism. Further, B-vitamin intake was based solely on diet, lacking information on supplements. Although we were able to confirm that seafood intake in this population was low, we were unable to adjust for other food sources of inorganic arsenic that may confound the findings, such as rice intake. Finally, since there are gene variants, for example, the common single nucleotide polymorphism in the gene for MTHFR, the 667 C→ T mutation, that lead to lower blood folate levels, the extent to which B-vitamin intake reflects internal levels of those vitamins, at least in part, is genetically determined. Additional research to evaluate the role of OCM related genetic variants and its impact on these relationships in this population would be useful.

5. CONCLUSIONS

Our study provides evidence that even at low levels of arsenic exposure and in well-nourished populations, OCM nutrient intake may affect the efficiency of arsenic metabolism. Further, our findings suggest vitamins B₆ and B₂, two previously understudied OCM vitamins, may play a stronger role in arsenic metabolism than folate in well-nourished protein-sufficient populations.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Abbreviations

As PC 1	Arsenic Metabolism Principal Component 1
As PC 2	Arsenic Metabolism Principal Component 2
BMI	Body Mass Index
CKD-EPI	Chronic Kidney Disease Epidemiology Collaboration
DFE	Dietary Folate Equivalent

DMA	Dimethylarsenate
eGFR	Estimate Glomerular Filtration Rate
FFQ	Food Frequency Questionnaire
HPLC/ICPMS	High Performance Liquid Chromatography/Inductively Coupled Plasma-Mass Spectrometry
iAs	Inorganic Arsenic
MMA	Monomethylarsonate
OCM	One-Carbon Metabolism
OCM PC 1	One-Carbon Metabolism Principal Component 1
OCM PC 2	One-Carbon Metabolism Principal Component 2
OCM PC 3	One-Carbon Metabolism Principal Component 3
OCM PC4	One-Carbon Metabolism Principal Component 4
PCA	Principal Component Analysis
RCT	Randomized Controlled Trial
ΣAs	Total arsenic

References

- Acharyya N, Deb B, Chattopadhyay S, Maiti S. Arsenic-induced antioxidant depletion, oxidative DNA breakage, and tissue damages are prevented by the combined action of folate and vitamin b12. *Biol Trace Elem Res.* 2015; 168:122–132. [PubMed: 25850544]
- Aposhian HV, Aposhian MM. Arsenic toxicology: Five questions. *Chem Res Toxicol.* 2006; 19:1–15. [PubMed: 16411650]
- Bailey LB. Dietary reference intakes for folate: The debut of dietary folate equivalents. *Nutr Rev.* 1998; 56:294–299. [PubMed: 9810807]
- Balakrishnan P, Vaidya D, Franceschini N, Voruganti VS, Gribble MO, Haack K, et al. Association of cardiometabolic genes with arsenic metabolism biomarkers in american indian communities: The strong heart family study (shfs). *Environ Health Perspect.* 2016
- Berg CJ, Daley CM, Nazir N, Kinlacheeny JB, Ashley A, Ahluwalia JS, et al. Physical activity and fruit and vegetable intake among american indians. *J Community Health.* 2012; 37:65–71. [PubMed: 21630108]
- Bhattacharjee SSC, Pal S. Additive beneficial effect of folic acid and vitamin b12 co-administration on arsenic induced oxidative damage in cardiac tissue in vivo. *Asian J Pharm Clin Res.* 2013; 6:64–69.
- Challenger F. Biological methylation. *Adv Enzymol Relat Subj Biochem.* 1951; 12:429–491. [PubMed: 14885024]
- Chen JW, Chen HY, Li WF, Liou SH, Chen CJ, Wu JH, et al. The association between total urinary arsenic concentration and renal dysfunction in a community-based population from central taiwan. *Chemosphere.* 2011; 84:17–24. [PubMed: 21458841]
- Chen JW, Wang SL, Wang YH, Sun CW, Huang YL, Chen CJ, et al. Arsenic methylation, gsto1 polymorphisms, and metabolic syndrome in an arseniasis endemic area of southwestern taiwan. *Chemosphere.* 2012; 88:432–438. [PubMed: 22440634]

- Chen YC, Guo YL, Su HJ, Hsueh YM, Smith TJ, Ryan LM, et al. Arsenic methylation and skin cancer risk in southwestern taiwan. *J Occup Environ Med.* 2003a; 45:241–248. [PubMed: 12661181]
- Chen YC, Su HJ, Guo YL, Hsueh YM, Smith TJ, Ryan LM, et al. Arsenic methylation and bladder cancer risk in taiwan. *Cancer Causes Control.* 2003b; 14:303–310. [PubMed: 12846360]
- Chen YC, Su HJ, Guo YL, Houseman EA, Christiani DC. Interaction between environmental tobacco smoke and arsenic methylation ability on the risk of bladder cancer. *Cancer Causes Control.* 2005; 16:75–81. [PubMed: 15868449]
- Chiou HY, Hsueh YM, Hsieh LL, Hsu LI, Hsu YH, Hsieh FI, et al. Arsenic methylation capacity, body retention, and null genotypes of glutathione s-transferase m1 and t1 among current arsenic-exposed residents in taiwan. *Mutat Res.* 1997; 386:197–207. [PubMed: 9219558]
- Chung JS, Haque R, Guha Mazumder DN, Moore LE, Ghosh N, Samanta S, et al. Blood concentrations of methionine, selenium, beta-carotene, and other micronutrients in a case-control study of arsenic-induced skin lesions in west bengal, india. *Environ Res.* 2006; 101:230–237. [PubMed: 16332366]
- Committee SHSS. The strong heart study: Cardiovascular disease in american indians, manual. 1989
- Council NR. Arsenic in drinking water, 2001 update. Washington DC: 2001.
- Council NR. Critical aspects of epa's iris assessment of inorganic arsenic: Interim report. Washington, DC: National Academies Press; 2013.
- Cullen WRRK. Arsenic speciation in the environment. *Chemical Reviews.* 1989; 89:713–764.
- Del Razo LM, Garcia-Vargas GG, Vargas H, Albores A, Gonsebatt ME, Montero R, et al. Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. A pilot study. *Arch Toxicol.* 1997; 71:211–217. [PubMed: 9101036]
- Del Razo LM, Garcia-Vargas GG, Valenzuela OL, Castellanos EH, Sanchez-Pena LC, Currier JM, et al. Exposure to arsenic in drinking water is associated with increased prevalence of diabetes: A cross-sectional study in the zimapan and lagunera regions in mexico. *Environ Health.* 2011; 10:73. [PubMed: 21864395]
- Fretts AM, Howard BV, McKnight B, Duncan GE, Beresford SA, Mete M, et al. Associations of processed meat and unprocessed red meat intake with incident diabetes: The strong heart family study. *Am J Clin Nutr.* 2012; 95:752–758. [PubMed: 22277554]
- Gamble MV, Liu X, Ahsan H, Pilsner R, Ilievski V, Slavkovich V, et al. Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in bangladesh. *Environ Health Perspect.* 2005; 113:1683–1688. [PubMed: 16330347]
- Gamble MV, Liu X, Ahsan H, Pilsner JR, Ilievski V, Slavkovich V, et al. Folate and arsenic metabolism: A double-blind, placebo-controlled folic acid-supplementation trial in bangladesh. *Am J Clin Nutr.* 2006; 84:1093–1101. [PubMed: 17093162]
- Gamble MV, Liu X, Slavkovich V, Pilsner JR, Ilievski V, Factor-Litvak P, et al. Folic acid supplementation lowers blood arsenic. *Am J Clin Nutr.* 2007; 86:1202–1209. [PubMed: 17921403]
- Gribble MO, Crainiceanu CM, Howard BV, Umans JG, Francesconi KA, Goessler W, et al. Body composition and arsenic metabolism: A cross-sectional analysis in the strong heart study. *Environ Health.* 2013; 12:107. [PubMed: 24321145]
- Hall M, Gamble M, Slavkovich V, Liu X, Levy D, Cheng Z, et al. Determinants of arsenic metabolism: Blood arsenic metabolites, plasma folate, cobalamin, and homocysteine concentrations in maternal-newborn pairs. *Environ Health Perspect.* 2007; 115:1503–1509. [PubMed: 17938743]
- Hall MN, Liu X, Slavkovich V, Ilievski V, Mi Z, Alam S, et al. Influence of cobalamin on arsenic metabolism in bangladesh. *Environ Health Perspect.* 2009a; 117:1724–1729. [PubMed: 20049124]
- Hall MN, Liu X, Slavkovich V, Ilievski V, Pilsner JR, Alam S, et al. Folate, cobalamin, cysteine, homocysteine, and arsenic metabolism among children in bangladesh. *Environ Health Perspect.* 2009b; 117:825–831. [PubMed: 19479028]
- Hall MN, Gamble MV. Nutritional manipulation of one-carbon metabolism: Effects on arsenic methylation and toxicity. *J Toxicol.* 2012; 2012:595307. [PubMed: 22523489]
- Hayakawa T, Kobayashi Y, Cui X, Hirano S. A new metabolic pathway of arsenite: Arsenic-glutathione complexes are substrates for human arsenic methyltransferase cyt19. *Arch Toxicol.* 2005; 79:183–191. [PubMed: 15526190]

- Heck JE, Gamble MV, Chen Y, Graziano JH, Slavkovich V, Parvez F, et al. Consumption of folate-related nutrients and metabolism of arsenic in bangladesh. *Am J Clin Nutr.* 2007; 85:1367–1374. [PubMed: 17490975]
- Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE. Methylation study of a population environmentally exposed to arsenic in drinking water. *Environ Health Perspect.* 1996; 104:620–628. [PubMed: 8793350]
- Howe CG, Niedzwiecki MM, Hall MN, Liu X, Ilievski V, Slavkovich V, et al. Folate and cobalamin modify associations between s-adenosylmethionine and methylated arsenic metabolites in arsenic-exposed bangladeshi adults. *J Nutr.* 2014; 144:690–697. [PubMed: 24598884]
- Hsueh YM, Chiou HY, Huang YL, Wu WL, Huang CC, Yang MH, et al. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. *Cancer Epidemiol Biomarkers Prev.* 1997; 6:589–596. [PubMed: 9264271]
- Jansen RJ, Argos M, Tong L, Li J, Rakibuz-Zaman M, Islam MT, et al. Determinants and consequences of arsenic metabolism efficiency among 4,794 individuals: Demographics, lifestyle, genetics, and toxicity. *Cancer Epidemiol Biomarkers Prev.* 2016; 25:381–390. [PubMed: 26677206]
- Kuo CC, Moon K, Thayer KA, Navas-Acien A. Environmental chemicals and type 2 diabetes: An updated systematic review of the epidemiologic evidence. *Curr Diab Rep.* 2013; 13:831–849. [PubMed: 24114039]
- Kuo CC, Howard BV, Umans JG, Gribble MO, Best LG, Francesconi KA, et al. Arsenic exposure, arsenic metabolism, and incident diabetes in the strong heart study. *Diabetes Care.* 2015; 38:620–627. [PubMed: 25583752]
- Lampe JW, Huang Y, Neuhouser ML, Tinker LF, Song X, Schoeller DA, et al. Dietary biomarker evaluation in a controlled feeding study in women from the women’s health initiative cohort. *Am J Clin Nutr.* 2017; 105:466–475. [PubMed: 28031191]
- Lee ET, Welty TK, Fabsitz R, Cowan LD, Le NA, Oopik AJ, et al. The strong heart study. A study of cardiovascular disease in american indians: Design and methods. *Am J Epidemiol.* 1990; 132:1141–1155. [PubMed: 2260546]
- Li L, Ekstrom EC, Goessler W, Lonnerdal B, Nermell B, Yunus M, et al. Nutritional status has marginal influence on the metabolism of inorganic arsenic in pregnant bangladeshi women. *Environ Health Perspect.* 2008; 116:315–321. [PubMed: 18335097]
- Lopez-Carrillo L, Gamboa-Loira B, Becerra W, Hernandez-Alcaraz C, Hernandez-Ramirez RU, Gandolfi AJ, et al. Dietary micronutrient intake and its relationship with arsenic metabolism in mexican women. *Environ Res.* 2016; 151:445–450. [PubMed: 27565879]
- Melak D, Ferreccio C, Kalman D, Parra R, Acevedo J, Perez L, et al. Arsenic methylation and lung and bladder cancer in a case-control study in northern chile. *Toxicol Appl Pharmacol.* 2014; 274:225–231. [PubMed: 24296302]
- Mendez MA, Gonzalez-Horta C, Sanchez-Ramirez B, Ballinas-Casarrubias L, Ceron RH, Morales DV, et al. Chronic exposure to arsenic and markers of cardiometabolic risk: A cross-sectional study in chihuahua, mexico. *Environ Health Perspect.* 2016; 124:104–111. [PubMed: 26068977]
- Moon K, Guallar E, Navas-Acien A. Arsenic exposure and cardiovascular disease: An updated systematic review. *Curr Atheroscler Rep.* 2012; 14:542–555. [PubMed: 22968315]
- Mossavar-Rahmani Y, Shaw PA, Wong WW, Sotres-Alvarez D, Gellman MD, Van Horn L, et al. Applying recovery biomarkers to calibrate self-report measures of energy and protein in the hispanic community health study/study of latinos. *Am J Epidemiol.* 2015; 181:996–1007. [PubMed: 25995289]
- Naranmandura H, Suzuki N, Suzuki KT. Trivalent arsenicals are bound to proteins during reductive methylation. *Chem Res Toxicol.* 2006; 19:1010–1018. [PubMed: 16918239]
- Naujokas MF, Anderson B, Ahsan H, Aposhian HV, Graziano JH, Thompson C, et al. The broad scope of health effects from chronic arsenic exposure: Update on a worldwide public health problem. *Environ Health Perspect.* 2013; 121:295–302. [PubMed: 23458756]
- Navas-Acien A, Umans JG, Howard BV, Goessler W, Francesconi KA, Crainiceanu CM, et al. Urine arsenic concentrations and species excretion patterns in american indian communities over a 10-

- year period: The strong heart study. *Environ Health Perspect.* 2009; 117:1428–1433. [PubMed: 19750109]
- NIH. Folate dietary supplement fact sheet. U.S. Department of Health & Human Services; 2016a.
- NIH. Riboflavin fact sheet for health professionals. U.S. Department of Health & Human Services; 2016b.
- NIH. Vitamin b12 dietary supplement fact sheet. U.S. Department of Health & Human Services; 2016c.
- NIH. Vitamin b6 dietary supplement fact sheet. US Department of Health and Human Services; 2016d.
- Nizam S, Kato M, Yatsuya H, Khalequzzaman M, Ohnuma S, Naito H, et al. Differences in urinary arsenic metabolites between diabetic and non-diabetic subjects in bangladesh. *Int J Environ Res Public Health.* 2013; 10:1006–1019. [PubMed: 23481591]
- Park JY, Vollset SE, Melse-Boonstra A, Chajes V, Ueland PM, Slimani N. Dietary intake and biological measurement of folate: A qualitative review of validation studies. *Mol Nutr Food Res.* 2013; 57:562–581. [PubMed: 23065735]
- Peters BA, Hall MN, Liu X, Parvez F, Sanchez TR, van Geen A, et al. Folic acid and creatine as therapeutic approaches to lower blood arsenic: A randomized controlled trial. *Environ Health Perspect.* 2015; 123:1294–1301. [PubMed: 25978852]
- Pilsner JR, Liu X, Ahsan H, Ilievski V, Slavkovich V, Levy D, et al. Folate deficiency, hyperhomocysteinemia, low urinary creatinine, and hypomethylation of leukocyte DNA are risk factors for arsenic-induced skin lesions. *Environ Health Perspect.* 2009; 117:254–260. [PubMed: 19270796]
- Prentice RL, Mossavar-Rahmani Y, Huang Y, Van Horn L, Beresford SA, Caan B, et al. Evaluation and comparison of food records, recalls, and frequencies for energy and protein assessment by using recovery biomarkers. *Am J Epidemiol.* 2011; 174:591–603. [PubMed: 21765003]
- Ralph Carmel, DWJ., editor. *Homocysteine in health and disease.* Cambridge University Press; 2001.
- Rhee JJ, Cho E, Willett WC. Energy adjustment of nutrient intakes is preferable to adjustment using body weight and physical activity in epidemiological analyses. *Public Health Nutr.* 2014; 17:1054–1060. [PubMed: 23701939]
- Scheer J, Findenig S, Goessler W, Francesconi KA, Howard B, Umans JG, et al. Arsenic species and selected metals in human urine: Validation of hplc/icpms and icpms procedures for a long-term population-based epidemiological study. *Anal Methods.* 2012; 4:406–413. [PubMed: 22685491]
- Shara NM, Wang H, Mete M, Al-Balha YR, Azalddin N, Lee ET, et al. Estimated gfr and incident cardiovascular disease events in american indians: The strong heart study. *Am J Kidney Dis.* 2012; 60:795–803. [PubMed: 22841159]
- Steinmaus C, Yuan Y, Bates MN, Smith AH. Case-control study of bladder cancer and drinking water arsenic in the western united states. *Am J Epidemiol.* 2003; 158:1193–1201. [PubMed: 14652304]
- Steinmaus C, Carrigan K, Kalman D, Atallah R, Yuan Y, Smith AH. Dietary intake and arsenic methylation in a u.S. Population. *Environ Health Perspect.* 2005; 113:1153–1159. [PubMed: 16140620]
- Steinmaus C, Bates MN, Yuan Y, Kalman D, Atallah R, Rey OA, et al. Arsenic methylation and bladder cancer risk in case-control studies in argentina and the united states. *J Occup Environ Med.* 2006; 48:478–488. [PubMed: 16688004]
- Tyler CR, Allan AM. The effects of arsenic exposure on neurological and cognitive dysfunction in human and rodent studies: A review. *Curr Environ Health Rep.* 2014; 1:132–147. [PubMed: 24860722]
- Vahter M. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. *Toxicol Lett.* 2000; 112–113:209–217.
- Vahter M. Mechanisms of arsenic biotransformation. *Toxicology.* 2002; 181–182:211–217.
- Wang SL, Chang FH, Liou SH, Wang HJ, Li WF, Hsieh DP. Inorganic arsenic exposure and its relation to metabolic syndrome in an industrial area of taiwan. *Environ Int.* 2007; 33:805–811. [PubMed: 17481731]
- Wu F, Molinaro P, Chen Y. Arsenic exposure and subclinical endpoints of cardiovascular diseases. *Curr Environ Health Rep.* 2014; 1:148–162. [PubMed: 25013752]

- Wu MM, Chiou HY, Hsueh YM, Hong CT, Su CL, Chang SF, et al. Effect of plasma homocysteine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid atherosclerosis. *Toxicol Appl Pharmacol.* 2006; 216:168–175. [PubMed: 16806340]
- Yu RC, Hsu KH, Chen CJ, Froines JR. Arsenic methylation capacity and skin cancer. *Cancer Epidemiol Biomarkers Prev.* 2000; 9:1259–1262. [PubMed: 11097236]
- Zablotska LB, Chen Y, Graziano JH, Parvez F, van Geen A, Howe GR, et al. Protective effects of b vitamins and antioxidants on the risk of arsenic-related skin lesions in bangladesh. *Environ Health Perspect.* 2008; 116:1056–1062. [PubMed: 18709164]

HIGHLIGHTS

- Greater intake of one-carbon metabolism (OCM) vitamins B₆ and B₂, was associated with arsenic metabolism (ASM) efficiency
- In principal component (PC) analyses, the PC reflecting greater OCM vitamin intake was also associated with enhanced ASM
- High vitamin B₆ and B₂ intake had an additive effect on ASM efficiency
- High folate with low B₆ was associated with reduced ASM, but high intake of both vitamins was associated with enhanced ASM




Figure 1. One-Carbon Metabolism, B-vitamins, and Arsenic Metabolism
 Methionine is activated by methionine adenosyltransferase to form S-adenosylmethionine (SAM). SAM provides the methyl group for most methylation reactions in the body (including arsenic methylation reactions), after which adenosylhomocysteine (SAH) is formed as a byproduct. SAH is hydrolyzed to homocysteine, which is then used in the transsulfuration pathway, or is regenerated into methionine via betaine or B₁₂ dependent pathways. Dietary folate is converted to 5-methyl tetrahydrofolate through B₆ and B₂ dependent reactions, which provides the methyl group for the regeneration of homocysteine to methionine via the B₁₂ pathway.




Figure 2. Pearson Correlation Matrix for Arsenic Species Percentages and Calorie-Corrected Nutrition Variables

Correlations and histograms of arsenic species percentages and calorie-corrected, using a residual analysis method of calorie-adjustment, nutrition variables (B₁₂ outlier not included).




Figure 3. Major dietary sources of one-carbon metabolism (OCM) nutrients

Foods listed under OCM nutrients are considered to be high dietary sources of that nutrient (provide 20% or more of the daily value). (NIH 2016a) Foods fortified with folic acid are not included in the figure because U.S. folic acid fortification occurred after the SHS baseline visit.

Table 1

Participant Characteristics by Arsenic Metabolism (N=405)

	N	iAs% median (IQR)	P-value ^a	MMA% median (IQR)	P-value ^a	DMA% median (IQR)	P-value ^a
Overall	405	7.1 (5.2, 10.7)		13.7 (11.3, 17.7)		78.2 (71.6, 83.3)	
Age (years)							
<55	159	8.0 (5.8, 11.7)		13.3 (11.3, 18.0)		77.8 (70.6, 82.1)	
55 to <65	128	6.9 (5.3, 10.6)		13.5 (11.2, 17.5)		79.5 (71.0, 83.5)	
65	118	6.6 (4.4, 9.5)	0.007	14.6 (11.3, 17.4)	0.92	77.9 (73.1, 83.7)	0.46
Sex							
Male	181	9.2 (6.3, 12.7)		16.2 (13.0, 19.5)		75.1 (68.6, 80.2)	
Female	224	6.4 (4.6, 9.0)	<0.001	12.6 (9.6, 15.1)	<0.001	80.9 (75.7, 84.9)	<0.001
Σ As (µg/L)							
0.70 – <7.10	135	7.0 (5.0, 10.5)		13.8 (11.3, 17.2)		78.8 (73.1, 82.4)	
7.10 – 14.0	136	6.9 (4.6, 10.5)		14.2 (10.6, 17.9)		78.7 (71.7, 84.3)	
> 14.0 – 87.2	134	8.0 (5.6, 11.5)	0.07	13.3 (11.5, 18.2)	0.87	77.3 (70.4, 82.6)	0.23
BMI (kg/m ³)							
<25	72	10.3 (7.7, 12.4)		18.0 (13.2, 21.8)		71.6 (65.6, 77.3)	
25 to <30	141	7.1 (5.1, 10.6)		14.2 (11.8, 17.9)		77.9 (72.4, 82.5)	
30	192	6.5 (4.6, 9.7)	<0.001	12.8 (10.1, 15.9)	<0.001	80.6 (75.0, 84.7)	<0.001
Smoking Status							
Never	114	6.1 (4.3, 9.1)		12.8 (9.4, 15.6)		80.3 (75.0, 86.1)	
Former	138	6.8 (4.8, 9.9)		13.5 (11.7, 17.7)		79.1 (72.6, 83.7)	
Current	153	9.3 (6.4, 12.6)	<0.001	14.7 (12.3, 18.6)	<0.001	76.1 (68.8, 80.8)	<0.001
Alcohol							
Never	66	5.9 (4.0, 9.2)		12.8 (9.7, 15.9)		80.4 (73.6, 85.5)	
Former	188	6.9 (4.6, 10.3)		13.3 (10.5, 17.2)		79.4 (73.3, 84.0)	
Current	151	8.8 (6.4, 12.3)	<0.001	14.7 (12.6, 18.8)	<0.001	76.2 (68.8, 81.0)	<0.001
eGFR (mL/min)							
60	367	5.5 (3.8, 8.3)		13.3 (9.6, 16.8)		80.1 (75.1, 85.2)	
>60	38	7.5 (5.4, 10.9)	0.001	13.7 (11.3, 18.0)	0.55	78.1 (71.2, 82.7)	0.06
Urine Creatinine (mg/dL)							

	N	iAs% median (IQR)	P-value ^d	MMA % median (IQR)	P-value ^d	DMA % median (IQR)	P-value ^d
<0.95	136	8.5 (5.9, 11.9)		13.4 (11.4, 16.7)		78.0 (71.2, 81.9)	
0.95–1.50	134	6.4 (4.4, 9.3)		13.6 (10.5, 16.9)		79.4 (73.6, 85.0)	
>1.50	135	7.1 (5.0, 11.4)	<0.001	14.7 (11.9, 19.0)	0.12	78.2 (69.4, 83.1)	0.02
Total Caloric Intake (kcal)							
<1,230	135	7.5 (5.1, 10.5)		13.4 (11.3, 16.5)		78.7 (72.1, 83.3)	
1,230–1,968	135	8.1 (5.4, 11.9)		14.2 (10.8, 19.8)		77.0 (69.5, 83.4)	
>1,968	135	6.7 (5.0, 10.5)	0.14	13.7 (11.5, 17.3)	0.36	79.3 (72.5, 83.5)	0.24
Vitamin B ₂ (mg) ^b							
<1.07	139	8.3 (5.4, 11.5)		14.1 (11.5, 18.8)		77.2 (69.9, 81.9)	
1.07–1.76	132	7.0 (4.9, 10.8)		13.3 (10.9, 17.8)		78.4 (72.0, 83.8)	
>1.76	134	6.9 (5.4, 10.1)	0.12	13.7 (10.8, 17.1)	0.39	79.0 (73.6, 83.5)	0.11
Vitamin B ₆ (mg) ^b							
<0.93	135	8.5 (5.6, 12.9)		13.6 (11.5, 18.4)		76.9 (70.5, 82.1)	
0.93–1.68	135	7.7 (5.1, 11.4)		14.3 (11.4, 18.5)		77.8 (69.7, 82.6)	
>1.68	135	6.7 (4.9, 9.3)	0.005	13.2 (10.2, 16.9)	0.05	80.2 (74.8, 84.2)	0.005
Folate (µg) ^b							
<144.1	135	8.5 (5.7, 12.8)		14.1 (12.3, 18.0)		76.9 (69.9, 81.4)	
144.1–285.2	135	6.9 (4.9, 10.5)		13.2 (10.5, 17.7)		79.2 (72.1, 84.4)	
>285.2	135	6.9 (5.0, 10.2)	0.03	13.7 (10.0, 17.9)	0.22	79.3 (71.8, 83.7)	0.04
Vitamin B ₁₂ (µg) ^b							
<2.20	136	8.0 (5.3, 11.5)		14.2 (11.2, 18.7)		77.3 (70.7, 82.2)	
2.20–4.41	134	6.8 (4.9, 10.3)		13.3 (11.2, 17.1)		79.5 (72.6, 83.6)	
>4.41	135	7.2 (5.3, 11.2)	0.15	13.9 (11.3, 17.7)	0.53	78.2 (71.3, 83.5)	0.21

ΣAs, total urinary inorganic arsenic; BMI, body mass index; eGFR, estimated glomerular filtration rate

^dKruskal-Wallis tests were used to compare methylation medians across variable categories

^bVitamins are displayed as crude values, not calorie-adjusted

Table 2
 Summary of Principal Components for Arsenic Species and Calorie-Adjusted Nutrition Variables

	As Metabolism PC1	As Metabolism PC2	OCM PC1	OCM PC3	OCM PC3	OCM PC4
Variance explained (%)	84.6	15.4	60.1	22.7	10.3	6.9
Standard deviation	1.59	0.68	1.55	0.95	0.64	0.52
Weights for iAs%	-0.55	-0.73	--	--	--	--
Weight for MMA%	-0.56	0.69	--	--	--	--
Weight for DMA%	0.63	-0.03	--	--	--	--
Weight for Vitamin B ₂	--	--	0.57	0.13	0.47	-0.66
Weight for Vitamin B ₆	--	--	0.53	-0.26	-0.79	-0.16
Weight for Folate	--	--	0.52	-0.46	0.37	0.62
Weight for Vitamin B ₁₂	--	--	0.36	0.84	-0.12	0.39

As, arsenic; PC, principal component; OCM, one-carbon metabolism

Table 3

Mean Difference (95% CI) in iAs%, MMA% and DMA% by Calorie-Adjusted Nutrition Tertiles (N=405)

Model	Model 1 ^a	Model 2 ^b	Model 3 ^c
Vitamin B₂ (mg)			
iAs%			
<1.073	0.00 (ref)	0.00 (ref)	0.00 (ref)
1.073 – 1.43	-0.09 (-1.19, 1.01)	-0.21 (-1.20, 0.79)	-0.29 (-1.35, 0.77)
>1.43	-0.90 (-2.00, 0.20)	-1.00 (-2.00, 0.00)	-0.68 (-1.89, 0.53)
MMA%			
<1.073	0.00 (ref)	0.00 (ref)	0.00 (ref)
1.073 – 1.43	-0.47 (-1.75, 0.81)	-0.59 (-1.71, 0.53)	-0.69 (-1.88, 0.50)
>1.43	-0.96 (-2.24, 0.33)	-1.36 (-2.48, -0.23)	-1.58 (-2.94, -0.22)
DMA%			
<1.073	0.00 (ref)	0.00 (ref)	0.00 (ref)
1.073 – 1.43	0.57 (-1.53, 2.67)	0.80 (-1.01, 2.61)	0.98 (-0.99, 2.90)
>1.43	1.86 (-0.25, 3.97)	2.36 (0.54, 4.18)	2.26 (0.06, 4.46)
Vitamin B₆ (mg)			
iAs%			
<0.936	0.00 (ref)	0.00 (ref)	0.00 (ref)
0.936 – 1.4241	-0.21 (-1.29, 0.88)	0.08 (-0.90, 1.06)	0.11 (-0.69, 1.39)
>1.4241	-1.92 (-3.01, -0.84)	-1.36 (-2.35, -0.37)	-1.18 (-2.32, -0.03)
MMA%			
<0.936	0.00 (ref)	0.00 (ref)	0.00 (ref)
0.936 – 1.4241	-1.28 (-2.55, -0.02)	-0.78 (-1.89, 0.34)	-0.85 (-2.00, 0.30)
>1.4241	-2.29 (-3.56, -1.03)	-1.57 (-2.69, -0.45)	-1.80 (-3.09, -0.51)
DMA%			
<0.936	0.00 (ref)	0.00 (ref)	0.00 (ref)
0.936 – 1.4241	1.49 (-0.58, 3.56)	0.69 (-1.10, 2.49)	0.74 (-1.12, 2.60)
>1.4241	4.21 (2.14, 6.28)	2.93 (1.13, 4.74)	2.98 (0.89, 5.07)
Folate (µg)			
iAs%			
<149	0.00 (ref)	0.00 (ref)	0.00 (ref)
149 – 266	-0.67 (-1.77, 0.42)	-0.40 (-1.40, 0.60)	-0.06 (-1.10, 0.98)
>266	-1.31 (-2.41, -0.21)	-0.80 (-1.79, 0.20)	0.14 (-1.07, 1.34)
MMA%			
<149	0.00 (ref)	0.00 (ref)	0.00 (ref)
149 – 266	-1.50 (-2.82, -0.27)	-0.93 (-2.06, 0.20)	-0.29 (-1.46, 0.88)
>266	-0.70 (-1.97, 0.58)	-0.18 (-1.30, 0.93)	1.27 (-0.08, 2.62)
DMA%			

Model	Model 1 ^a	Model 2 ^b	Model 3 ^c
<149	0.00 (ref)	0.00 (ref)	0.00 (ref)
149 – 266	2.22 (0.13, 4.32)	1.33 (-0.50, 3.16)	0.34 (-1.55, 2.23)
>266	2.01 (-0.09, 4.10)	0.98 (-0.83, 2.79)	-1.41 (-3.59, 0.78)
Vitamin B₁₂ (μg)			
iAs%			
<2.20	0.00 (ref)	0.00 (ref)	0.00 (ref)
2.20 – 3.93	0.36 (-0.74, 1.46)	0.52 (-0.47, 1.51)	0.74 (-0.31, 1.78)
>3.93	-0.27 (-1.37, 0.83)	-0.55 (-1.54, 0.44)	-0.06 (-1.16, 1.04)
MMA%			
<2.20	0.00 (ref)	0.00 (ref)	0.00 (ref)
2.20 – 3.93	-0.51 (-1.80, 0.77)	-0.44 (-1.57, 0.68)	0.15 (-1.03, 1.32)
>3.93	0.01 (-1.28, 1.29)	-0.37 (-1.49, 0.76)	0.54 (-0.69, 1.78)
DMA%			
<2.20	0.00 (ref)	0.00 (ref)	0.00 (ref)
2.20 – 3.93	0.15 (-1.96, 2.26)	-0.08 (-1.90, 1.74)	-0.89 (-2.79, 1.01)
>3.93	0.26 (-1.85, 2.38)	0.92 (-0.90, 2.74)	-0.48 (-2.48, 1.51)

^aAdjusted for total log arsenic and log urinary creatinine

^bAdjusted for total log arsenic, log urinary creatinine age, sex, center, smoking, alcohol, eGFR, BMI

^cAdjusted for total log arsenic, log urinary creatinine age, sex, center, smoking, alcohol, eGFR, BMI, all b-vitamins of interest

Table 4

Mean Difference^a (95% CI) in iAs%, MMA%, DMA% and Arsenic Principal Components by Nutrition Tertiles and OCM Principal Components

	As Metabolism PC1	As Metabolism PC2	iAs%	MMA%	DMA%
<i>Calorie-Corrected Nutrition Tertiles</i>					
Vitamin B₂ (mg)					
<1.073	0.00 (ref)	0.00 (ref)	0.00 (ref)	0.00 (ref)	0.00 (ref)
1.073 – 1.43	0.14 (-0.18, 0.47)	-0.05 (-0.20, 0.11)	-0.21 (-1.20, 0.79)	-0.59 (-1.71, 0.53)	0.80 (-1.01, 2.61)
>1.43	0.43 (0.10, 0.75)	-0.03 (-0.18, 0.13)	-1.00 (-2.00, 0.00)	-1.36 (-2.48, -0.23)	2.36 (0.54, 4.18)
Vitamin B₆ (mg)					
<0.936	0.00 (ref)	0.00 (ref)	0.00 (ref)	0.00 (ref)	0.00 (ref)
0.936 – 1.4241	0.12 (-0.20, 0.45)	-0.11 (-0.27, 0.04)	0.08 (-0.90, 1.06)	-0.78 (-1.89, 0.34)	0.69 (-1.10, 2.49)
>1.4241	0.53 (0.20, 0.86)	0.00 (-0.15, 0.16)	-1.36 (-2.35, -0.37)	-1.57 (-2.69, -0.45)	2.93 (1.13, 4.74)
Folate (µg)					
<149	0.00 (ref)	0.00 (ref)	0.00 (ref)	0.00 (ref)	0.00 (ref)
149 – 266	0.24 (-0.09, 0.57)	-0.06 (-0.22, 0.09)	-0.40 (-1.40, 0.60)	-0.93 (-2.06, 0.20)	1.33 (-0.50, 3.16)
>266	0.18 (-0.15, 0.51)	0.10 (-0.06, 0.25)	-0.80 (-1.79, 0.20)	-0.18 (-1.30, 0.93)	0.98 (-0.83, 2.79)
Vitamin B₁₂ (µg)					
<2.20	0.00 (ref)	0.00 (ref)	0.00 (ref)	0.00 (ref)	0.00 (ref)
2.20 – 3.93	-0.02 (-0.35, 0.31)	-0.14 (-0.29, 0.02)	0.52 (-0.47, 1.51)	-0.44 (-1.57, 0.68)	-0.08 (-1.90, 1.74)
>3.93	0.17 (-0.16, 0.50)	0.04 (-0.12, 0.19)	-0.55 (-1.54, 0.44)	-0.37 (-1.49, 0.76)	0.92 (-0.90, 2.74)
<i>One-Carbon Metabolism Principal Components</i>					
OCM PC1	0.13 (0.04, 0.21)	0.00 (-0.04, 0.04)	-0.33 (-0.59, -0.07)	-0.38 (-0.67, -0.08)	0.71 (0.23, 1.18)
OCM PC2	0.03 (-0.11, 0.17)	-0.02 (-0.09, 0.04)	0.00 (-0.43, 0.43)	-0.17 (-0.65, 0.32)	0.17 (-0.62, 0.95)
OCM PC3	-0.14 (-0.35, 0.07)	0.02 (-0.08, 0.12)	0.29 (-0.34, 0.92)	0.48 (-0.23, 1.19)	-0.77 (-1.91, 0.38)
OCM PC4	-0.21 (-0.46, 0.05)	0.07 (-0.04, 0.20)	0.27 (-0.51, 1.05)	0.89 (0.01, 1.77)	-1.16 (-2.58, 0.27)

As, arsenic; PC, principal component; OCM, one-carbon metabolism

^aResults adjusted for total log arsenic, log urinary creatinine, age, sex, center, smoking, alcohol, eGFR, BMI